logo-loader
viewRedx Pharma Plc

Redx Pharma poster assesses the direct tumour targeting of cancer candidate

New data will be unveiled later Monday at a cancer conference in Glasgow

researcher filling a vial
A phase I/IIa trial of the porcupine inhibitor is set to resume in the first half of next year

Redx Pharma Plc (LON:REDX) will unveil a poster presentation outlining some encouraging data pointing to the direct tumour targeting effects of RXC004, its porcupine inhibitor.

The new information was garnered using colorectal and pancreatic cancer cell lines.

Redx concluded that cancer cells carrying RNF43 mutations or RSPO fusions were sensitive to RXC004 in its tests.

As such, the company believes it would be most effective as a single therapy in patients with cancers carrying those markers.

Patient screening 

This, it added, would support by a genetically-defined patient selection strategy for ongoing RXC004 clinical studies.

A phase I/IIa trial of the porcupine inhibitor is set to resume in the first half of next year in patients with what are described as “advanced malignancies”.

A poster summarising the latest data will be presented to the National Cancer Research Institute in Glasgow from noon Monday.

"We are delighted to showcase some of the fantastic science happening at Redx,” said the company’s chief medical officer, Richard Armer.

“We are encouraged by the preclinical data presented at the NCRI, which demonstrates the exquisite sensitivity of specific genetically defined cancer models to our Porcupine inhibitor, RXC004.

“The strength of these data highlight some of the broad and multiple options available for the future development of this programme as we look to re-enter the clinic in the first half of 2019."

Quick facts: Redx Pharma Plc

Price: 7.25 GBX

AIM:REDX
Market: AIM
Market Cap: £9.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

2 days, 14 hours ago

2 min read